HSF1 and prostate cancer: Here, we explore the prognostic value of HSF1 in prostate cancer by analyzing independent mRNA gene expression datasets and two separate, large prostate cancer patient tissue microarray (TMA) cohorts: one radical prostatectomy cohort with extensive clinical information and long term follow-up (15.7 years) and a second separate cohort comprising of regionally advanced to distant metastatic tumors.